Clinical TrialsSearch results
Number of results: 818
Completed
- A Phase 1 Mass Balance Study of Oral [14C] TAS-115 in Healthy Adult Male Subjects
- Chronic fibrosing interstitial lung diseases with a progressive phenotype
- Huang Jinhong
- 2021-09-07
Completed
- A phase 1 open-label study evaluating the effects of food on TAS-205 in healthy volunteers
- Duchenne Muscular Dystrophy
- Takeda Shin'ichi
- 2023-06-25
Completed
- A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Axatilimab When Administered by Intravenous Infusion to Healthy Japanese Participants
- GVHD, healthy voluteer
- Ono Shintaro
- 2023-02-27
Completed
- A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB054707 When Administered Orally to Healthy Japanese Participants
- Inflammatory disease
- On Shintaro
- 2021-10-18
Completed
- A phase I clinical study of KSP-0243
- Healthy Condition
- Shimizu Yoshitaka
- 2021-01-20
Completed
- A Phase I Dose Escalation and Food Effect Study of Isotretinoin
- Severe acne vulgaris
- Toida Tsuneyuki
- 2022-11-25
Completed
- A PHASE I, TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF RAY121 IN HEALTHY VOLUNTEERS
- Healthy Volunteer
- Kai Megumi
- 2022-08-04
Completed
- A prospective study of investigating the efficacy of FOLFIRI plus Aflibercept as a 2nd line therapy after progression during FOLFOXIRI plus Bevacizumab in unrescetable / metastatic colorectal cancer (CRC) patients.
- Colorectal Cancer
- Oki Eiji
- 2019-04-18
Completed
- A Randomized, Active-comparator, Observer-blind, Phase I/II/III Study to Demonstrate the Immunogenicity of a Single Booster Dose of DS-5670a in Adults and Elderly Received a Primary Series of Approved COVID-19 Vaccine
- Prevention of infectious disease by SARS-CoV-2
- Inoguchi Akihiro
- 2021-12-28
Completed
- A randomized, participant and investigator-blinded, placebo-controlled, single ascending intravenous and single subcutaneous dose study to assess the safety, tolerability and pharmacokinetics of CMK389 in Japanese healthy participants
- Japanese healthy participants
- Yamada Hiroyuki
- 2022-01-21